Navigation Links
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Date:8/19/2007

is trial. Efficacy evaluations will include the measure of target lesions (per RECIST), and the quantization of symptom relief. Further details of this trial can be found at http://www.clinicaltrials.gov.

The other five sites currently participating in this Phase II trial are: 1) the Hematology Oncology Services of Arkansas in Little Rock, Arkansas, 2) the Dana-Farber Cancer Institute in Boston, MA. 3) Mount Sinai in New York City, 4) Lahey Clinic in Burlington, MA. and 5) Scott & White Memorial Hospital in Temple TX.

About Atiprimod

Atiprimod is an orally bio-available small molecule drug that displays multiple mechanisms of action. The drug has been shown to be antiangiogenic, inhibit secretion of VEGF and IL-6, elicit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including Akt and STAT3. The drug is presently in two clinical trials: a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients. Callisto earlier announced in June, 2006 interim data from a Phase I trial of Atiprimod in advanced cancer patients. The patients who were entered into this trial had growing tumors and symptoms that were no longer controlled by the standard therapies utilized. During treatment, three of the five advanced carcinoid patients had measurable tumor regressions and loss of many of the debilitating symptoms of this disease.

About Carcinoid Cancer

Carcinoid tumors, or carcinoids, originate in hormone-producing cells of the gastrointestinal (GI) tract, the respiratory tract, the hepatobiliary (liver) system and the reproductive glands. The most common site of origin is the GI tract, with tumors often developing in the rectum, and other sections of the small intestine. Approximately 7,000 cases of carcinoid cancer are diag
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Ill. , Dec. 19, 2014   Hospira, ... leading provider of injectable drugs and infusion technologies, today ... Morgan 33rd Annual Healthcare Conference on Wednesday, Jan. 14, ... presentation is scheduled to begin at 10:30 a.m. Pacific ... available to all interested parties through a live audiocast ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, ... SRNE ;  Sorrento), an oncology company developing new ... Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ... based therapy, announced today that the companies have ... next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for ...
(Date:12/19/2014)... LOS ALTOS, Calif. , Dec. 18, 2014 ... of a new generation of equipment for the ... today the release of the new Luminary™ Profiler, ... highly accurate light-based measurement in a cost-effective, portable ... to meet the specific needs of the cannabis ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... October 12, 2011 Leading health ... titles freely available through UN developing world research access ... scientific, technical and medical information products and services, today ... books to Research4Life , a public-private partnership working ...
... Mass., Oct. 11, 2011 Boston Scientific Corporation (NYSE: ... results for the third quarter ended September 30, 2011 on ... call will be hosted by Hank Kucheman, who becomes Boston ... Executive Vice President and Chief Financial Officer. A ...
Cached Medicine Technology:Elsevier Offers 950 New Health Titles to Research4Life 2Elsevier Offers 950 New Health Titles to Research4Life 3Boston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results 2
(Date:12/21/2014)... As testosterone therapy lawsuit filings ... blood clots from using testosterone products such as AndroGel ... that the male hormone testosterone may increase the risk ... in the Proceedings of the National Academy of Sciences ... of male rats with naturally occurring colon cancer. Dr. ...
(Date:12/21/2014)... December 21, 2014 Concept Plus, LLC. ... firm headquartered in Fairfax, VA., today announced it has ... Fast 50 list, which ranks the fastest growing government contracting ... 2009 to 2013. , This is the first year that ... ranked # 20 with a 95.92% compound annual growth rate. ...
(Date:12/20/2014)... 2014 MissyDress, a distinguished special dress ... lovers. The business has drastically cut prices to all ... everyone until Jan. 30, 2015. Many of the hottest ... V-neck dresses, lace dresses, and more. , A spokesman ... every day. Whether A-line princess prom dresses or sweetheart ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Dress company LunaDress ... dresses, and announced its Christmas Sale, offering big discounts on ... “Every girl has an idea to own a perfect wedding ... for your wedding dress, then come to LunaDress. Many different ... for you. Visit our website now and enjoy the current ...
(Date:12/20/2014)... News) -- The holidays can be anything but joyous ... trees, scented candles and other allergy triggers. "The ... have been packed away in dank basements or dusty ... patients," Dr. Rachna Shah, an affiliate faculty member at ... Loyola news release. Shah, who is also an ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:Holiday Trimmings Can Trigger Allergies 2
... AUSTIN, Texas, May 21 From June 9-11 in ... lead a "DRTV Management Boot,Camp" tailor-made for nutraceutical and ... can do very well in an,informercial or short form ... from Iceland Health, for example," says Sarnow. "But there ...
... Georgacas and Mark ... Mishek as its newest members, ... Board of Directors of ClearWay Minnesota(SM) approved $1.4 million in,new ... to reduce exposure to secondhand smoke by advancing smoke-free,policy efforts ...
... research into the causes of cervical cancer appears to lend ... that could help prevent the disease. , According to a ... Chapel Hill, persistent infection with human papillomavirus (HPV) could be ... the second most common cancer in women worldwide. , ...
... QVC,s Pink Ribbon Beauty Broadcast Benefits the Breast Cancer ... Shoppers are sure to be,tickled pink this May when ... on Tuesday, May 27 at 1 AM (ET) and ... from top beauty,brands, with a portion of the proceeds ...
... to give keynote speech June 9 in Atlanta, ... U.S. Centers for Disease Control and Prevention (CDC), will,discuss ... address at the American Water Works Association,s Annual Conference,& ... Georgia., As one of the leading public health ...
... In this challenging,marketplace, pharmaceutical sales people have ... to effectively,represent their brands and ensure that ... Practices, LLC,s white paper "Best Practices in ... ) addresses how the Sales force,effectiveness and ...
Cached Medicine News:Health News:Direct Response TV Course on Nutraceutical/Cosmeceutical Products to Premiere in New York City 2Health News:ClearWay Minnesota(SM) Board Approves $1.4 Million in New Grants to Reduce Tobacco's Harm 2Health News:ClearWay Minnesota(SM) Board Approves $1.4 Million in New Grants to Reduce Tobacco's Harm 3Health News:UNC study firms up promise of potential new cervical cancer screening tool 2Health News:A Touch of Pink Never Looked So Good 2Health News:CDC Director to Address Public Health and Drinking Water at ACE08 2
... CMGS-1 Color Mini-Ganzfeld Stimulator is an advanced, ... integrated with your existing LKC system or ... visual electrodiagnostic test systems. Using LKCs ... smallest commercial Ganzfeld to meet ISCEV (International ...
... UTAS-E 3000 is the most advanced ... and accurate measurements of retinal and ... easy-to-use software available drives this powerful ... as adjustable contrast pattern stimulation, rapid ...
... CC cages are designed to facilitate an ... approach. These are interbody cages allowing radicular ... interve rtebral space and of the foramina, ... are particularly indicated for major lumbar instabilities.,CC ...
... SHELLGEL is a sterile nonpyrogenic, transparent ... SHELLGEL contains 12 mg/mL of high molecular ... hyaluronate dissolved in physiological saline. In the ... is 105,000 cps (105 Pa s) at ...
Medicine Products: